Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02164006 · ClinicalTrials.gov registry record · Phase 1
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
A Phase 1 study of Hodgkin's Lymphoma, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 4
- Study locations
NCT02164006: Completed Phase 1 study of Hodgkin's Lymphoma, sponsored by TG Therapeutics.
NCT02164006 is a Phase 1 study of Hodgkin's Lymphoma that has completed, run by TG Therapeutics. The registered enrollment target is 16 participants, below the 104-participant average among 18 other Hodgkin's Lymphoma trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02164006, a Phase 1 study of Hodgkin's Lymphoma, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.
Primary Outcome
To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities
Conditions Studied
Interventions
- DRUG TGR-1202 + brentuximab vedotin
Study Locations (4)
California
- TG Therapeutics Investigational Trial Site - Duarte
- TG Therapeutics Investigational Trial Site - San Diego
Florida
- TG Therapeutics Investigational Trial Site - Sarasota
Michigan
- TG Therapeutics Investigational Trial Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-06-11 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
What the finished NCT02164006 record still lists
NCT02164006 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 104-participant average among 18 other Hodgkin's Lymphoma trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which TGR-1202 + brentuximab vedotin is the first listed.
NCT02164006 reports a single indexed study location in California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT02164006 about?
NCT02164006 is a clinical study titled "Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients". The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.
What is the current status of trial NCT02164006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-06-11. Estimated completion is 2016-05.
What conditions does trial NCT02164006 study?
This clinical trial studies the following conditions: Hodgkin's Lymphoma.
What interventions are being tested in trial NCT02164006?
The interventions under investigation include: TGR-1202 + brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT02164006?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02164006 being conducted?
This trial has 4 study locations across California, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02164006's enrollment target sits among peer trials
16 18th of 18 higher than 1 of 18 other Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
RECRUITING · Phase 1
-
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
RECRUITING · Phase 1
-
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
COMPLETED · Phase 1
-
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
COMPLETED · Phase 1
-
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI